Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registryResearch in context [PDF]
EClinicalMedicine, 2023 Summary: Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/
Jon Salmanton-García +115 more
doaj +9 more sources
A Phase 1 Multiple-Dose, Open-Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women. [PDF]
Clin Transl SciABSTRACT In accordance with the Centers for Disease Control and Prevention recommendations, pregnant women and those with a recent pregnancy (i.e., lactating) are considered at high risk of developing severe COVID‐19 and qualify for treatment with nirmatrelvir/ritonavir.
Gerhart J +7 more
europepmc +2 more sources
Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation studyResearch in context [PDF]
EClinicalMedicine, 2023 Summary: Background: Molnupiravir and nirmatrelvir-ritonavir have emerged as promising options for COVID-19 treatment, but direct comparisons of their effectiveness have been limited.
Eric Yuk Fai Wan +10 more
doaj +3 more sources
Nirmatrelvir/ritonavir reduced mortality in severe or critical COVID-19 patients: a multicenter retrospective cohort study [PDF]
Frontiers in MedicineBackgroundPatients with severe or critical coronavirus disease 2019 (COVID-19) remain at a high risk of mortality. Although nirmatrelvir/ritonavir has demonstrated efficacy in non-severe COVID-19 patients with high-risk factors, its effectiveness in ...
Heng Zhao +11 more
doaj +2 more sources
Prevalence of potentially inappropriate use of antiviral therapy with simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalised patients: a retrospective study in Beijing, China [PDF]
BMJ Open Respiratory ResearchBackground While simnotrelvir-ritonavir and nirmatrelvir-ritonavir, the oral antiviral agents targeting the 3C-like proteases, are widely used in China, robust data on their appropriate use remain limited in hospitalised patients.
Hui Zhang +9 more
doaj +2 more sources
Effectiveness comparison of nirmatrelvir/ritonavir versus molnupiravir in COVID-19 patients with comorbidities in Taiwan: a multi-centre electronic health record study [PDF]
BMC Infectious DiseasesBackground COVID-19 patients frequently present with various comorbidities. Two developed antiviral medications, nirmatrelvir/ritonavir and molnupiravir, have been utilized in COVID-19 patients; but comparisons of the effectiveness between nirmatrelvir ...
Wen-Kuang Lin +17 more
doaj +2 more sources
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice [PDF]
European Cardiology ReviewCardiovascular disease is associated with progression to severe COVID-19 and patients with the condition are among those in whom early antiviral therapy should be warranted.
Andrea Di Lenarda +4 more
doaj +3 more sources
Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir [PDF]
Infectious Diseases and TherapyIntroduction We compared the effectiveness and virological clearance (VC) at day 7 (T7) post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2-infected patients at high risk (HR) for clinical progression.
Francesca Bai +23 more
doaj +2 more sources
VV116 or Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19 [PDF]
New England Journal of Medicine, 2023 To the Editor: Cao and colleagues (Feb. 2 issue)1 report that the oral antiviral agent VV116 was noninferior to nirmatrelvir–ritonavir in alleviating Covid-19–related ...
Fleming, Thomas R, Lin, Dan-Yu
exaly +3 more sources
Infectious Diseases and TherapyIntroduction Limited data exist regarding real-world utilization of nirmatrelvir/ritonavir. We identified predictors of nirmatrelvir/ritonavir use among Veterans Affairs (VA) outpatients nationally. Methods We conducted a retrospective cohort study among
Haley J. Appaneal +8 more
exaly +2 more sources